NovaVive Signs a Co-Operation Agreement with Hoken Biotechnology to Register and Market Amplimune™ in Asia

NovaVive Inc.

NovaVive is a private Canadian immunobiology company founded in July, 2014. The Company acquired an advanced veterinary immunotherapeutic platform based on mycobacterium cell wall fraction (MCWF) technology with regulator-approved products for cattle, horses and dogs. These products are currently sold to veterinarians in the U.S.A., Canada, Australia and New Zealand. The Company's head office is located in Napanee, Ontario, Canada.

Sign up to stay up-to-date with NovaVive news.

Recent News

Immunocidin® with Chemotherapy Extends Survival Time in Study with Canine Lymphoma and Osteosarcoma Patients

Positive data from a retrospective study using Immunocidin® with chemotherapy in dogs with Lymphoma and Osteosarcoma were presented at the Veterinary Cancer Society Annual Conference by Dr. Jeannette Kelly, vet oncologist.

learn more

Amplimune® Administered in Calves Prior to Shipment Shows Economic Benefit

Data from a University of Minnesota research study presented by Dr. Luciano Caixeta at the AABP annual conference in St. Louis, MO last week shows an economic benefit to the use of Amplimune in calves prior to shipping.

learn more

Amplimune® Administered in Calves Prior to Shipment Demonstrates a Reduced Likelihood of Pneumonia Upon Arrival

Amplimune® given to calves prior to shipment has been shown to reduce the likelihood of pneumonia on arrival. Data from a 1,360-calf study was presented at the 2019 American Dairy Science Association Annual Meeting today.

learn more

Follow NovaVive on Social Media.